3 Hospitals Chain, Crop Protection Company and Footwear Brand Stocks With a Strong Future Roadmap: Krishna Institute of Medical Sciences, Insecticides India and Bata India
- November 18, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Krishna Institute of Medical Sciences, Insecticides India and Bata India: ROE of 10.4% to 11.4% and FY22 to FY26 revenue CAGR of 9.3% to 23.8%. Prices as of 17 Nov 2026.
Quick Answer
The three hospital, crop chemical and footwear stocks to watch are Krishna Institute of Medical Sciences, Insecticides India and Bata India. Their return on equity ranges from 10.4% to 11.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.3% to 23.8%. Insecticides India has the highest return on equity at 11.4%, while Krishna Institute of Medical Sciences has the fastest revenue growth at 23.8% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.
Hospital, crop chemical and footwear stocks let investors follow companies that serve a growing part of the Indian economy. Krishna Institute of Medical Sciences, Insecticides India and Bata India cover a hospitals chain, a crop protection company and a footwear brand.
This list covers three hospital, crop chemical and footwear stocks with complete current figures: Krishna Institute of Medical Sciences, Insecticides India and Bata India. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Hospital, Crop Chemical and Footwear Stocks?
Hospital, crop chemical and footwear stocks are listed companies that run multi-speciality hospitals across southern and eastern states, make pesticides and crop protection chemicals for farmers, and design and sell footwear through a wide store network. Their earnings depend on patient numbers, crop demand and footwear spending.
Hospital, Crop Chemical and Footwear Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Krishna Institute of Medical Sciences | 768.3 | 28,495 | 146.5 | 59.6 | 10.7 | 1.89 |
| Insecticides India | 545.5 | 1,507 | 12.0 | 21.9 | 11.4 | 0.13 |
| Bata India | 633.25 | 8,187 | 56.0 | 37.0 | 10.4 | 0.87 |
On valuation, Insecticides India trades at a P/E below the industry P/E, while Krishna Institute of Medical Sciences and Bata India trade above it, which reflects the growth the market already expects. Readers comparing hospital, crop chemical and footwear stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Hospital, Crop Chemical and Footwear Stocks Have a Strong Roadmap in India?
Hospital, crop chemical and footwear stocks have a strong roadmap in India because wider access to quality hospital care, steady farm input demand and rising spending on branded footwear keep widening the market for these companies.
- Hospitals. Families seek advanced care closer to home.
- Crop protection. Farmers protect their yields.
- Footwear. Shoppers prefer trusted brands.
Why Krishna Institute of Medical Sciences Features Among These Hospital, Crop Chemical and Footwear Stocks
Among the hospital, crop chemical and footwear stocks on this list, Krishna Institute of Medical Sciences, known as KIMS Hospitals, runs a network of multi-specialty hospitals in Telangana, Andhra Pradesh and other states, with strengths in cardiac, neuro and transplant care.
Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%. Net profit for FY26 was Rs 242 crore, a net margin of 6.2%.
In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6.
Roadmap: The company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.
What to watch: Track bed additions, occupancy and revenue per occupied bed.
Why Insecticides India Features Among These Hospital, Crop Chemical and Footwear Stocks
Among the private hospitals, pesticide and shoe brand shares on this list, Insecticides India is a Delhi-based crop protection company that makes and sells insecticides, herbicides and fungicides to farmers through a wide network of dealers and distributors.
Revenue rose from Rs 1,508 crore in FY22 to Rs 2,152 crore in FY26, a compound annual growth rate of 9.3%. Net profit grew from Rs 107 crore in FY22 to Rs 139 crore in FY26, which works out to a compound annual growth rate of 6.7%.
The company has a return on equity of 11.4%, a debt to equity ratio of 0.13 and a market capitalisation of Rs 1,507 crore. The stock trades at a P/E of 12.0, below the industry P/E of 21.9.
Roadmap: The company is launching new formulations and growing its own brands, which supports better margins. Rising demand for crop protection from Indian farmers supports steady volumes.
What to watch: Follow monsoon trends, new product launches and technical raw material costs.
Why Bata India Features Among These Hospital, Crop Chemical and Footwear Stocks
Among the three companies on this list, Bata India is the country’s largest footwear retailer, selling under the Bata, Hush Puppies, Power and other brands through a large network of company-owned and franchised stores.
The company has a return on equity of 10.4%, a debt to equity ratio of 0.87 and a market capitalisation of Rs 8,187 crore. The stock trades at a P/E of 56.0, above the industry P/E of 37.0.
Revenue rose from Rs 2,444 crore in FY22 to Rs 3,595 crore in FY26, a compound annual growth rate of 10.1%. Net profit grew from Rs 103 crore in FY22 to Rs 134 crore in FY26, which works out to a compound annual growth rate of 6.8%. In the June 2026 quarter, revenue grew 4.0% year on year to Rs 997 crore, while net profit rose 23.0% to Rs 64.0 crore.
Roadmap: The company is widening its range into sports, casual and premium footwear and adding stores in smaller towns. A trusted brand and deep retail reach support steady demand.
What to watch: Follow store additions, premium product mix and same-store sales.
Krishna Institute of Medical Sciences vs Insecticides India vs Bata India on Key Financials
The table below sets the three hospital, crop chemical and footwear stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Krishna Institute of Medical Sciences | 1,671 | 3,931 | 23.8% | 242 | 6.2% |
| Insecticides India | 1,508 | 2,152 | 9.3% | 139 | 6.5% |
| Bata India | 2,444 | 3,595 | 10.1% | 134 | 3.7% |
Insecticides India posts the highest return on equity in this group at 11.4%. Krishna Institute of Medical Sciences combines the largest FY26 revenue at Rs 3,931 crore with the fastest revenue growth, a 23.8% compound annual rate. A useful habit with hospital, crop chemical and footwear stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Hospital, Crop Chemical and Footwear Stocks
Every theme carries risks that deserve a check before any decision. For these hospital, crop chemical and footwear stocks, the main points are: Long-term private hospitals, pesticide and shoe brand shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Capacity ramp up. New hospitals take time to fill beds and reach full returns.
- Season and monsoon. Crop protection sales follow rain and pest cycles.
- Consumer spending. Sales follow festivals, incomes and consumer mood.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter hospital, crop chemical and footwear stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Hospital, Crop Chemical and Footwear Stocks
Hospital, crop chemical and footwear stocks reward investors who follow demand trends, order books and margins together. Krishna Institute of Medical Sciences, Insecticides India and Bata India each have a clear plan to grow. Based on the 17 November 2026 close, Krishna Institute of Medical Sciences trades at Rs 768.3, Insecticides India at Rs 545.5 and Bata India at Rs 633.25.
Download the Univest iOS App or Univest Android App to track hospital, crop chemical and footwear stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are hospital, crop chemical and footwear stocks?
Ans. Hospital, crop chemical and footwear stocks are listed companies that run multi-speciality hospitals across southern and eastern states, make pesticides and crop protection chemicals for farmers, and design and sell footwear through a wide store network. Their earnings depend on patient numbers, crop demand and footwear spending. This list looks at three of them, Krishna Institute of Medical Sciences, Insecticides India and Bata India, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.
Which hospital, crop chemical and footwear stocks are covered in this list?
Ans. This list covers Krishna Institute of Medical Sciences, Insecticides India and Bata India. Based on the 17 November 2026 close, Krishna Institute of Medical Sciences traded at Rs 768.3, Insecticides India at Rs 545.5 and Bata India at Rs 633.25. Their return on equity ranges from 10.4% to 11.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.3% to 23.8%.
Why do hospital, crop chemical and footwear stocks have a strong future roadmap in India?
Ans. Hospital, crop chemical and footwear stocks have a strong roadmap in India because wider access to quality hospital care, steady farm input demand and rising spending on branded footwear keep widening the market for these companies. The main drivers are as follows. Hospitals. Families seek advanced care closer to home. Crop protection. Farmers protect their yields. Footwear. Shoppers prefer trusted brands. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Krishna Institute of Medical Sciences performed financially?
Ans. Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%. Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6. Looking ahead, the company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.
How has Insecticides India performed financially?
Ans. Revenue rose from Rs 1,508 crore in FY22 to Rs 2,152 crore in FY26, a compound annual growth rate of 9.3%. Net profit grew from Rs 107 crore in FY22 to Rs 139 crore in FY26, which works out to a compound annual growth rate of 6.7%. The company has a return on equity of 11.4%, a debt to equity ratio of 0.13 and a market capitalisation of Rs 1,507 crore. The stock trades at a P/E of 12.0, below the industry P/E of 21.9. Looking ahead, the company is launching new formulations and growing its own brands, which supports better margins. Rising demand for crop protection from Indian farmers supports steady volumes.
How has Bata India performed financially?
Ans. Revenue rose from Rs 2,444 crore in FY22 to Rs 3,595 crore in FY26, a compound annual growth rate of 10.1%. Net profit grew from Rs 103 crore in FY22 to Rs 134 crore in FY26, which works out to a compound annual growth rate of 6.8%. In the June 2026 quarter, revenue grew 4.0% year on year to Rs 997 crore, while net profit rose 23.0% to Rs 64.0 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.87 and a market capitalisation of Rs 8,187 crore. The stock trades at a P/E of 56.0, above the industry P/E of 37.0. Looking ahead, the company is widening its range into sports, casual and premium footwear and adding stores in smaller towns. A trusted brand and deep retail reach support steady demand.
What risks should investors check before buying hospital, crop chemical and footwear stocks?
Ans. Investors should check a few risks before buying hospital, crop chemical and footwear stocks. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Season and monsoon. Crop protection sales follow rain and pest cycles. Consumer spending. Sales follow festivals, incomes and consumer mood. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of hospital, crop chemical and footwear stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.